Next, we examined the treatment efficacy in ACC patients with NOTCH1, KDM6A, BRAF mutations, and MYB structural variants, as these genes were commonly observed and associated with poorer prognosis in ACC [23,24]. This evidence concerns the gene NOTCH1 and adrenal cortex carcinoma.